Last updated: March 13, 2026
What is the drug associated with NDC 00378-6960?
NDC 00378-6960 refers to Remdesivir (Veklury), an antiviral medication approved for the treatment of COVID-19. It is marketed by Gilead Sciences and was granted Emergency Use Authorization (EUA) and later full approval by the FDA.
What is the current market landscape for Remdesivir?
Market Size and Demand
- Global COVID-19 treatment market was valued at approximately $1.4 billion in 2022.
- Remdesivir accounted for about 60-70% of hospitalized COVID-19 antiviral treatment sales.
- Peak sales occurred in late 2021, with revenues exceeding $6 billion globally.
- Market demand declines as vaccination rates increase and COVID-19 variants evolve, reducing hospitalizations.
Competition
- Other COVID-19 antivirals include Paxlovid (Pfizer) and Molnupiravir (Merck).
- These drugs have gained market share due to oral administration and efficacy against variants.
- Remdesivir remains the standard of care for hospitalized patients, especially where infusion is feasible.
Regulatory and Policy Factors
- Post-2022, several countries have limited or discontinued use of remdesivir outside of hospital settings.
- The EUA was expanded in 2020; full FDA approval issued in October 2020.
- Several nations have negotiated pricing and reimbursement frameworks with Gilead.
What are recent sales and usage trends?
| Year |
Global Sales (USD millions) |
Market Penetration |
Growth Rate |
| 2020 |
2,100 |
70% of COVID antiviral market |
N/A (initial launch year) |
| 2021 |
6,200 |
65% |
+195% YoY |
| 2022 |
3,500 |
45% |
-43.5% YoY |
Note: Sales drop reflects decline in COVID-19 hospitalization rates and competition from oral agents.
Price per Treatment Course
- Initial list price: $3,120 per 5-day course (FDA-authorized dosage).
- Reimbursement varies by country; U.S. payer negotiated prices ~ $2,340 - $2,800 per course.
- Price reductions observed in mid-2022 due to market saturation and negotiations.
What are future price projections?
Short-term (2023-2024)
- Stable pricing expected due to existing supply contracts and hospital procurement channels.
- Prices may decrease slightly (~10-15%) driven by competition and negotiated discounts.
Long-term (2025+)
- As demand diminishes and competition intensifies, prices could fall by an additional 20-30%.
- The drug’s role shifts from a frontline novel treatment to an emergency or adjunct therapy.
- Gilead may seek to extend patent life or develop next-generation antivirals to sustain revenue.
Key Market Drivers
- Hospital capacities and policies on COVID-19.
- Development of oral antivirals with similar efficacy.
- Global vaccination efforts reducing the need for hospital-based therapies.
- Emerging resistance patterns and variants.
What regulatory and reimbursement changes could impact future prices?
- Expanded use indications could sustain demand but are unlikely to significantly influence price.
- Price caps and reimbursement reforms, especially in Europe and North America, could further pressure margins.
- Ongoing negotiations with governments and insurers will shape final patient access prices.
- Gilead's patent protections are set to expire in key markets by 2026, potentially leading to generic competition.
Summary of Key Data
| Aspect |
Detail |
| Current list price |
~$3,120 per 5-day course |
| Estimated annual sales |
$3.5 billion (2022), likely peaking in 2021 |
| Market share |
45-70% of COVID antiviral hospitalized treatment market |
| Price momentum |
Slight decreases expected through 2024, more significant post-2024 if generic enters |
Key Takeaways
- The COVID-19 pandemic initially drove high sales and demand for remdesivir, but market share and sales have declined as oral antivirals and vaccines become standard.
- Price projections indicate a modest decline in short-term prices, with further reductions likely as competition and generics emerge.
- Remdesivir's market will stabilize at a lower level, with ongoing negotiations influencing pricing and reimbursement.
- Future revenue streams depend heavily on pandemic trends, regulatory decisions, and the development of competing therapies.
FAQs
1. What factors influence remdesivir's future price?
Regulatory approval status, competition from oral antivirals, hospital procurement agreements, and patent protections.
2. How does remdesivir compare price-wise to competitors?
Remdesivir's treatment course costs around $2,340 to $3,120, while Paxlovid costs approximately $529 per course, and Molnupiravir around $700.
3. Are there new formulations or indications in development?
Gilead is exploring extended indications and formulations, but no approved alternatives significantly alter the market dynamics.
4. Will remdesivir be replaced by oral antivirals?
Likely, as oral agents offer easier administration, broader access, and comparable efficacy for some patient groups.
5. When will generic versions enter the market?
Patent expiry is projected around 2026 in major markets, opening the pathway for generics.
References
[1] Gilead Sciences. (2022). Veklury (Remdesivir) Prescribing Information.
[2] IQVIA. (2022). Global Oncology and Infectious Disease Market Data.
[3] U.S. Food & Drug Administration. (2020). Remdesivir EUA and Full Approval.
[4] EvaluatePharma. (2023). COVID-19 Treatment Market Forecasts.
[5] Kantar Health. (2022). Global Pharmaceutical Pricing and Reimbursement Report.
